Cargando…
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patie...
Autor principal: | Bernards, René |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980300/ https://www.ncbi.nlm.nih.gov/pubmed/36750414 http://dx.doi.org/10.1002/1878-0261.13391 |
Ejemplares similares
-
Web-Based Medical Examinations During the COVID-19 Era: Reconsidering Learning as the Main Goal of Examination
por: Manteghinejad, Amirreza
Publicado: (2021) -
Therapeutics for Dengue: Recommendations for Design and Conduct of Early-Phase Clinical Trials
por: Simmons, Cameron P., et al.
Publicado: (2012) -
Time to reconsider the role of ribavirin in Lassa fever
por: Salam, Alex Paddy, et al.
Publicado: (2021) -
Email Use Reconsidered in Health Professions Education: Viewpoint
por: De Gagne, Jennie C, et al.
Publicado: (2020) -
Engaging adolescents with HIV to ensure better health and more informed research
por: Oliveras Rodriguez, Carlo A
Publicado: (2017)